Tags: Drug.

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design since it differs from AB-FUBINACA only by the replacement of the iso-propyl group with a tert-butyl group.

ADB-FUBINACA.png
CAS number
1445583-51-6
IUPAC name
N-(1-Amino-33-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide

Loading...

This page contains content from the copyrighted Wikipedia article "ADB-FUBINACA"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.